SEBOCLEARTM-MP
Balanced Microbiota in Ageless Skin
1 / SEBOCLEARTM-MP
Skin impurities
only a problem in puberty?
Female Children
Different Young
ethnicity adults
Male Adults
2 / SEBOCLEARTM-MP
The vicious cycle of acne development
Four input factors with mutual deleterious influence
3 / SEBOCLEARTM-MP
SEBOCLEARTM-MP in a nutshell
Balanced Microbiota in Ageless Skin
• All-rounder from the leaves of Maclura
cochinchinensis
• Optimizes the skin microbiota by
Propionibacterium acnes inhibition
• Shuts down inflammatory arachidonic
acid pathway
• Prevents 5α-reductase from forming DHT
• Resets the morphology of sebocytes
• Provides even, youthful-looking skin
4 / SEBOCLEARTM-MP
Sebum
The Gore-Tex for the skin
6. Sebum 1. Sebaceous gland
release of lipids over produces sebum
the degeneration zone by holocrine
into the sebaceous duct secretion
2. Sebaceous duct;
5. Sebocytes Stem cells
start to differentiate into
accumulate lipids precursor cells
4. Peripheral layer 3. Precursor cells
is built up by pushed develop into sebocytes
precursor cells by division and
differentiation
5 / SEBOCLEARTM-MP
Oil map of the body
and colonization of pores with Probionibacterium acnes
Porphyrines -
visualisation
by UV - illumination
6 / SEBOCLEARTM-MP
Dysbalanced microbiota
Trigger factor for acne
A. Sebaceous gland C. Propionibacterium acnes E. Pustule
is stimulated to increase colonise entrapped formed by sebum,
the sebum production, sebum; initiation of Propionibacterium acnes
leading to oily skin immunological reaction and pus
B. Blackhead D. Papule
generated by pore due to response to
clogging and oxidation bacterial infection
of melanin
7 / SEBOCLEARTM-MP
Blocking inflammation
Inhibition of Arachidonic acid pathways
8 / SEBOCLEARTM-MP
Bioflavonoids
of Maclura cochinchinensis
• Maclura cochinchinensis is also known as
cockspur thorn
• Grows in the forests of Southeast Asia,
Northern Australia and East Africa
• The plant was used in the traditional
“soga-batik” in Indonesia
• The young leaves and fruits of the plant
can be eaten
• The extract from the roots is known as
Chuanposhi in China
• The leaves are rich in bioflavonoids
9 / SEBOCLEARTM-MP
Active compounds in SEBOCLEARTM-MP
HPLC fingerprint of bioflavonoids of the isoflavone class
10 / SEBOCLEARTM-MP
Active compounds in SEBOCLEARTM-MP
Stability of bioflavonoids of the isoflavone class
Method:
Storage test at different conditions
and HPLC analysis
Implementation:
Determination of prenylated isoflavones
by HPLC
Result:
Completely stable at room temperature.
Storage at 40 °C and 20 °C (expose to
light) led to a decomposition of only
2.7 % and 4.2 % prenylated isoflavones
respectively
11 / SEBOCLEARTM-MP
The mode of action
Reduces oily skin and spots in multiple ways
12 / SEBOCLEARTM-MP
SEBOCLEARTM-MP
Balanced Microbiota in Ageless Skin
Scientifically confirmed effects:
• Regulates the skin microbiota
(in-vitro study)
• Directly inhibits steroid 5α-reductase
(in-vitro study)
• Reprograms sebocytes (in-vitro study)
• Shuts down inflammation (in-vitro study)
• Has retinoic - acid - like activity
(in-vitro study)
• Regulates the skin microbiome
(in-vivo study)
• Reduces axillar malodour (in-vivo study)
• Reduces signs of acne (in-vivo study)
• Provides even, youthful-looking skin
(in-vivo study)
13 / SEBOCLEARTM-MP
SEBOCLEARTM-MP regulates
the skin microbiota (in-vitro study)
Test design In-vitro growth inhibitory assay
Test subjects Bacterial skin microbiota strains
Test formulations Dilution series of SEBOCLEARTM-MP in Mueller-Hinton broth
Application period 24 – 48 hours, depending on the strain
Primary endpoint Minimal inhibitory concentration (MIC)
14 / SEBOCLEARTM-MP
SEBOCLEARTM-MP regulates the skin microbiota
Selective inhibition of P. acnes (in-vitro study)
15 / SEBOCLEARTM-MP
SEBOCLEARTM-MP selectively acts in the moist
and sebaceous body region
16 / SEBOCLEARTM-MP
SEBOCLEARTM-MP directly inhibits
steroid 5α-reductase (in-vitro study)
Test design In-vitro enzyme inhibition assay
Test subjects Recombinant human steroid 5α-reductase isoform I
Test formulations Assay buffer with increasing concentrations of SEBOCLEARTM-MP
Application period 30 min
Primary endpoint Reduction of enzymatic activity
17 / SEBOCLEARTM-MP
SEBOCLEARTM-MP directly inhibits
steroid 5α-reductase (in-vitro study)
18 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reprograms sebocytes
(in-vitro study)
Test design In-vitro cell culture assay
Test subjects Human dermal primary sebocytes (face), female donor with oily skin, age 46
Test formulations Cell culture medium without supplement
Cell culture medium with 0.1 % propanediol
Cell culture medium with 0.1 % SEBOCLEARTM-MP
Application period 48 hours
Primary endpoint Cell vitality
19 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reprograms sebocytes
(in-vitro study)
20 / SEBOCLEARTM-MP
SEBOCLEARTM-MP shuts down inflammation
(in-vitro study)
Test design In-vitro enzyme inhibition assay
Test subjects Recombinant human COX-1, COX-2 and 5-LOX
Test formulations Assay buffer with 0, 0.1 and 0.01 % SEBOCLEARTM-MP
Application period 3 min (COX-1); 5 min (COX-2); 20 min (5-LOX)
Primary endpoint Reduction of enzymatic activity
21 / SEBOCLEARTM-MP
SEBOCLEARTM-MP shuts down inflammation
(in-vitro study)
22 / SEBOCLEARTM-MP
SEBOCLEARTM-MP has retinoic-acid-like activity
(in-vitro study)
Test design In-vitro receptor binding assay
Test subjects Recombinant human RAR and RXR
Test formulations Assay buffer with 0.1 and 0.01 % SEBOCLEARTM-MP
Application period 180 min (RAR), 60 min (RXR)
Primary endpoint Replacement of control ligand
23 / SEBOCLEARTM-MP
SEBOCLEARTM-MP has retinoic-acid-like activity
(in-vitro study)
24 / SEBOCLEARTM-MP
SEBOCLEARTM-MP
Balanced Microbiota in Ageless Skin
-42 % Crow`s feet counts
-34 % Active sebaceous glands
-16 % Crow`s feet volume
-12 % Porphyrins
+43 % Firmness
+23 % Elasticity
-38 % Total Comedones
-36 % Blackheads
-36 % Wrinkles counts
-41 % Whiteheads
-9 % Wrinkles volume
-22 % Red spots
-12 % Propionibacterium acnes
-35 % Total lesions
-32 % Axillar malodour
25 / SEBOCLEARTM-MP
SEBOCLEARTM-MP regulates
the skin microbiome (in-vivo study)
Test design Application study
Test subjects 3 female subjects with healthy, oily, Caucasian skin ; 18 – 45 years (average 28.7)
Test formulations Emulsion containing 3 % SEBOCLEARTM-MP
Application area Face
Application period 28 days
Application frequency Twice daily
Primary endpoint Shannon index: diversity of the skin’s microbiome
26 / SEBOCLEARTM-MP
SEBOCLEARTM-MP regulates
the skin microbiome (in-vivo study)
27 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces axillar malodour
(in-vivo study)
Test design Double-blind, placebo controlled, randomised
Test subjects 20 subjects (11 male, 9 female) with pronounced axillar odour; 35 – 64 years (average 52.6)
Test formulations Spray containing 0 % SEBOCLEARTM-MP (placebo)
Spray containing 1 % SEBOCLEARTM-MP
Application area Axilla
Application period 1 day
Application frequency Once
Primary endpoint Axillar malodour
Secondary endpoint Colony forming unit count after 6 hours of application
28 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces axillar malodour
(in-vivo study)
29 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces the fraction
of coryneform bacteria (in-vivo study)
30 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces the signs of acne
(in-vivo study)
Test design Double-blind, placebo controlled, randomised
Test subjects 21 female subjects with healthy, oily Caucasian skin; 16 – 24 years (average 19.4)
Test formulations Emulsion containing 0 % SEBOCLEARTM-MP (placebo)
Emulsion containing 3 % SEBOCLEARTM-MP
Application area Hemiface
Application period 84 days
Application frequency Twice daily
Primary endpoint Inflammatory spots count: VISIA
Porphyrin count, photos: VISIA
Number of active sebaceous glands: Sebufix
Secondary endpoint Comedones and lesion number, skin scoring evaluation:
Objective assessment of visible effects by a dermatologist at the beginning, at day 28 and
day 84 of the study
31 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces total lesion count
Characteristic lesions in acne-prone skin
3. Papules
4. Pustules
2. Whiteheads
1. Blackheads
32 / SEBOCLEARTM-MP
SEBOCLEARTM-MP decreases the number of
active sebaceous glands and controls sebum (in-vivo study)
33 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces porphyrins and
pore visibility (in-vivo study)
34 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces the number of
comedones (in-vivo study)
35 / SEBOCLEARTM-MP
SEBOCLEARTM-MP is effective against
blackheads and whiteheads (in-vivo study)
36 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces total lesion count
(in-vivo study)
37 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces inflammatory spots
and visibly improves blemished skin (in-vivo study)
38 / SEBOCLEARTM-MP
SEBOCLEARTM-MP improves all symptoms of
acne prone skin
39 / SEBOCLEARTM-MP
SEBOCLEARTM-MP provides even, youthful-
looking skin (in-vivo study)
Test design Double-blind, placebo controlled, randomised
Test subjects 21 female subjects with healthy, oily Caucasian skin; 45 – 64 years (average 56.9)
Test formulations Emulsion containing 0 % SEBOCLEARTM-MP (placebo)
Emulsion containing 3 % SEBOCLEARTM-MP
Application area Hemiface
Application period 84 days
Application frequency Twice daily
Primary endpoint Firmness / elasticity: Cutometer MPA580 (2 mm probe)
Wrinkles / roughness: PRIMOS
Secondary endpoint Wrinkle appearance and skin texture:
Objective assessment of visible effects by a dermatologist at the beginning, at day 28 and
day 84 of the study
40 / SEBOCLEARTM-MP
SEBOCLEARTM-MP improves skin firmness
and elasticity (in-vivo study)
41 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces the wrinkle number
(in-vivo study)
42 / SEBOCLEARTM-MP
SEBOCLEARTM-MP reduces the wrinkle volume
(in-vivo study)
43 / SEBOCLEARTM-MP
SEBOCLEARTM-MP visually improves the wrinkle
appearance (in-vivo study)
44 / SEBOCLEARTM-MP
Marketing
concepts and claims
Teenager Treatments:
Face and body care suitable for impure skin with antimicrobial properties.
SEBOCLEARTM-MP supports the reduction of pimples.
Retinoic-acid-like activity for a cleaner and youthful-looking skin.
Deodorant application with SEBOCLEARTM-MP for less axillar malodour.
Ideal combination of activity to improve impure skin and reduce wrinkles.
Reduces sebum and decreases the pores.
SEBOCLEARTM-MP supports the optimization of skin microbiota and skin microbiome
and visibly improves impure skin.
Deodorant application for a longtime reduction of axillar malodour.
Reduces the number of sebaceous glands.
Reduction of acne and sebum.
Shuts down inflammation.
45 / SEBOCLEARTM-MP
Information
Presentation SEBOCLEARTM-MP 05/2018
Utilisation of this document or parts thereof as well as product names for commercial or industrial
applications is subject to explicit written approval by RAHN AG. This information is based on our own
experience to date and we believe it to be reliable. It is intended only as a guide to use at your discretion
and risk. We cannot guarantee favourable results and assume no liability in connection with its use, or
the use of the methods or products described. None of this information is to be taken as a license to
operate under, or a recommendation to infringe patents.
46 / SEBOCLEARTM-MP
THANK YOU
FOR YOUR ATTENTION
47 / SEBOCLEARTM-MP